DaVita HealthCare Partners Inc. (NYSE:DVA) was upgraded by investment analysts at Raymond James Financial Inc. from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Tuesday.

Several other analysts also recently weighed in on DVA. Wells Fargo & Co. reissued a “buy” rating on shares of DaVita HealthCare Partners in a report on Saturday, June 4th. Zacks Investment Research raised DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $87.00 target price for the company in a report on Tuesday, July 5th. TheStreet downgraded DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a report on Monday, August 8th. JPMorgan Chase & Co. boosted their target price on DaVita HealthCare Partners from $74.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, August 9th. Finally, Citigroup Inc. assumed coverage on DaVita HealthCare Partners in a report on Tuesday, September 6th. They issued a “neutral” rating and a $71.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $76.50.

DaVita HealthCare Partners (NYSE:DVA) opened at 63.60 on Tuesday. The firm’s 50-day moving average price is $67.46 and its 200-day moving average price is $73.22. The stock has a market cap of $13.16 billion, a P/E ratio of 37.00 and a beta of 1.07. DaVita HealthCare Partners has a 12 month low of $61.36 and a 12 month high of $78.94.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/davita-healthcare-partners-inc-dva-upgraded-to-outperform-by-raymond-james-financial-inc.html

DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings data on Monday, August 8th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.98 by $0.03. The business earned $3.72 billion during the quarter, compared to analysts’ expectations of $3.67 billion. DaVita HealthCare Partners had a return on equity of 16.48% and a net margin of 2.51%. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.95 EPS. On average, analysts predict that DaVita HealthCare Partners will post $3.76 earnings per share for the current year.

In other news, insider Jeanine Marie Jiganti sold 1,291 shares of the stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $78.51, for a total transaction of $101,356.41. Following the completion of the transaction, the insider now directly owns 5,716 shares of the company’s stock, valued at approximately $448,763.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Michael David Staffieri sold 20,262 shares of the company’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $73.09, for a total value of $1,480,949.58. Following the completion of the sale, the chief operating officer now owns 52,279 shares in the company, valued at approximately $3,821,072.11. The disclosure for this sale can be found here. Insiders own 2.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Checchi Capital Advisers LLC boosted its stake in DaVita HealthCare Partners by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 1,556 shares of the company’s stock worth $120,000 after buying an additional 37 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in DaVita HealthCare Partners during the second quarter worth $147,000. Mizuho Asset Management Co. Ltd. boosted its stake in DaVita HealthCare Partners by 78.7% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 2,191 shares of the company’s stock worth $169,000 after buying an additional 965 shares in the last quarter. Feltz Wealth PLAN Inc. purchased a new stake in DaVita HealthCare Partners during the second quarter worth $186,000. Finally, Global X Management Co. LLC boosted its stake in DaVita HealthCare Partners by 59.2% in the second quarter. Global X Management Co. LLC now owns 2,422 shares of the company’s stock worth $187,000 after buying an additional 901 shares in the last quarter. Institutional investors and hedge funds own 83.65% of the company’s stock.

DaVita HealthCare Partners Company Profile

DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).

5 Day Chart for NYSE:DVA

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.